Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir‐Enhanced Tipranavir

@article{Vourvahis2007MechanismsOP,
  title={Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir‐Enhanced Tipranavir},
  author={M. Vourvahis and A. Kashuba},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2007},
  volume={27}
}
  • M. Vourvahis, A. Kashuba
  • Published 2007
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
    • Tipranavir is a nonpeptidic protease inhibitor that has activity against human immunodeficiency virus strains resistant to multiple protease inhibitors. Tipranavir 500 mg is coadministered with ritonavir 200 mg. Tipranavir is metabolized by cytochrome P450 (CYP) 3A and, when combined with ritonavir in vitro, causes inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in addition to induction of glucuronidase and the drug transporter P‐glycoprotein. As a result, drug‐drug interactions… CONTINUE READING
    View on Wiley
    ncbi.nlm.nih.gov
    45 Citations
    Highly Influencial Citations
    3
    Background Citations
    9

    Paper Mentions

    Blog Post
    ABACAVIR
    New Drug Approvals
    4 June 2019
    45 Citations
    Citation Type

    Citation Type

    Metabolism-Mediated Drug Interactions Associated with Ritonavir-Boosted Tipranavir in Mice
    • 21
    • PDF
    Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
    • 31
    • PDF
    Tipranavir: A Review of its Use in Therapy of HIV Infection
    • PDF
    Tipranavir: a review of its use in the management of HIV infection.
    • 30
    • Highly Influenced
    Drug interactions with antiretrovirals and warfarin
    • 29
    Drug Interactions with New and Investigational Antiretrovirals
    • 51
    • PDF
    Induction Effects of Ritonavir: Implications for Drug Interactions
    • 139
    Pharmacokinetic Interaction of Vicriviroc with Other Antiretroviral Agents
    The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition
    • 98
    • PDF
    Toxicity of HIV protease inhibitors: clinical considerations
    • 32

    References

    SHOWING 1-10 OF 236 REFERENCES
    Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir
    • 88
    Tipranavir: A Protease Inhibitor From a New Class With Distinct Antiviral Activity
    • P. Yeni
    • Medicine
    • Journal of acquired immune deficiency syndromes
    • 2003
    • 34
    Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.
    • 119
    Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
    • 52
    • PDF
    The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
    • 126
    • PDF
    Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers
    • 54
    • PDF
    Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor lopinavir/ritonavir in liver‐transplanted HIV‐infected patients
    • M. Vogel, E. Voigt, +6 authors U. Spengler
    • Medicine
    • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
    • 2004
    • 87
    Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
    • 328
    The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
    • 97
    • PDF
    Tacrolimus and Lopinavir/Ritonavir Interaction in Liver Transplantation
    • 47